-
Co-Diagnostics Highlights Global Tuberculosis Initiatives and CoSara Advancements
NASDAQ: $CODX Strategic Focus on Global Health Co-Diagnostics, Inc. recently announced its participation in three major global tuberculosis (TB) events throughout November. These engagements underscore the company’s commitment to addressing one of the world’s most persistent infectious disease challenges through advanced molecular diagnostics. CoSara’s Progress in India A central theme of the announcement is the…
-
Sanofi’s $2.2 Billion Bet: What Their Acquisition of an HBV Vaccine Maker Means for Global Health
NASDAQ: $SNY In a move that sent ripples through the pharmaceutical landscape, Sanofi recently announced its acquisition of a Hepatitis B (HBV) vaccine maker for a staggering $2.2 billion. This strategic purchase, detailed in a recent article from Pharmaceutical Technology, isn’t just a financial transaction; it represents a significant investment in global public health and…